INFANTS' MOTRIN CONCENTRATED DROPS OTC
Generic Name and Formulations:
Ibuprofen 50mg/1.25mL; berry-flavored susp; original or dye-free; alcohol-free.
McNeil Consumer Healthcare
Indications for INFANTS' MOTRIN CONCENTRATED DROPS:
Minor aches and pain. Fever.
Use appropriate formulation and give every 6–8 hours. <6months: not recommended. 12–17lbs: 50mg. 18–23lbs: 75mg. 24–35lbs: 100mg. 36–47lbs: 150mg. 48–59lbs: 200mg. 60–71lbs: 250mg. 72–95lbs: 300mg.
Aspirin allergy. Immediately before or after cardiac surgery.
Increased risk of severe stomach bleeding or persistent sore throat (do not use >2 days or children <3 years). History of GI disorders (eg, heartburn, bleeding ulcers). Increased risk of heart attack or failure, and stroke. Hypertension. Heart disease. Recent stroke. Liver cirrhosis. Renal disease. Asthma. Dehydration. Reevaluate if no relief within 24 hours of treatment; pain or fever persists or worsens >3 days. Pregnancy. Nursing mothers.
Avoid aspirin or other pain relievers. Increased risk of GI bleed with anticoagulants, corticosteroids, other OTC or Rx NSAID-containing products (eg, ibuprofen, naproxen, others), or prolonged use. Caution with diuretics.
NSAID (propionic acid deriv.).
GI upset/bleed, symptoms of heart problems or stroke (eg, trouble breathing, feel faint, slurred speech), redness, swelling, allergic reactions; discontinue if occur.
Susp—1oz, 4oz; Drops—½ oz, 1oz
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Reduced Risk for Multiple Sclerosis Linked to Greater Sun Exposure
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Incidence of Delayed Traumatic Intracranial Hemorrhage Low in Older Adults With Blunt Head Trauma
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Accelerated Cognitive Decline Associated With Retinopathy
- Treatment Effects Often Exaggerated in Early Clinical Studies